Paper Details
- Home
- Paper Details
The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson's Disease.
Author: LissBirgit, StriessnigJörg
Original Abstract of the Article :
The motor symptoms of Parkinson's disease (PD) mainly arise from degeneration of dopamine neurons within the substantia nigra. As no disease-modifying PD therapies are available, and side effects limit long-term benefits of current symptomatic therapies, novel treatment approaches are needed. The on...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1146/annurev-pharmtox-010818-021214
データ提供：米国国立医学図書館（NLM）
L-Type Calcium Channels: A Potential Target for Neuroprotective Therapy in Parkinson's Disease
Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the brain. This review explores the potential of L-type calcium channels (LTCCs) as a drug target for neuroprotective therapy in PD. The authors discuss the role of LTCCs in neuronal function and their vulnerability to the degenerative processes associated with PD. They review the rationale for investigating isradipine, an LTCC blocker, as a potential neuroprotective agent for PD, highlighting the ongoing phase III clinical trial STEADY-PD.
A New Frontier in Parkinson's Disease Treatment: Targeting L-Type Calcium Channels
The authors propose that LTCCs may be a promising target for neuroprotective therapy in PD. They discuss the potential of isradipine, an LTCC blocker, to protect dopamine neurons from degeneration. The ongoing phase III clinical trial STEADY-PD is investigating the efficacy of isradipine in treating PD, offering hope for new and effective treatments for this debilitating disease. This research highlights the importance of exploring novel targets and developing innovative therapies for neurodegenerative disorders.
Protecting the Brain: The Promise of L-Type Calcium Channel Blockers
This review explores the potential of LTCC blockers, such as isradipine, as neuroprotective agents for PD. The authors highlight the importance of understanding the role of LTCCs in neuronal function and their vulnerability to the degenerative processes associated with PD. The ongoing phase III clinical trial STEADY-PD is investigating the efficacy of isradipine in treating PD, offering hope for new and effective treatments for this debilitating disease. Just as a camel adapts to the harsh desert environment, researchers are constantly seeking new ways to protect the brain from neurodegeneration.
Dr.Camel's Conclusion
This review explores the potential of L-type calcium channels (LTCCs) as a drug target for neuroprotective therapy in Parkinson's disease (PD). The authors discuss the role of LTCCs in neuronal function and their vulnerability to the degenerative processes associated with PD. They highlight the ongoing phase III clinical trial STEADY-PD, which is investigating the efficacy of isradipine, an LTCC blocker, as a potential neuroprotective agent for PD. This research underscores the importance of exploring novel targets and developing innovative therapies for neurodegenerative disorders. Just as a camel adapts to the harsh desert environment, researchers are constantly seeking new ways to protect the brain from neurodegeneration.
Date :
- Date Completed 2020-05-14
- Date Revised 2021-08-18
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.